Van Cutsem E - Search Results

1

Randomized trial of TAS-102 for refractory metastatic colorectal cancer.

Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A; RECOURSE Study Group. Mayer RJ, et al. Among authors: van cutsem e. N Engl J Med. 2015 May 14;372(20):1909-19. doi: 10.1056/NEJMoa1414325. N Engl J Med. 2015. PMID: 25970050 Free article. Clinical Trial.

2

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C. Rougier P, et al. Among authors: van cutsem e. Lancet. 1998 Oct 31;352(9138):1407-12. doi: 10.1016/S0140-6736(98)03085-2. Lancet. 1998. PMID: 9807986 Clinical Trial.

3

A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer.

Van Cutsem E, Pozzo C, Starkhammar H, Dirix L, Terzoli E, Cognetti F, Humblet Y, Garufi C, Filez L, Gruia G, Cote C, Barone C. Van Cutsem E, et al. Ann Oncol. 1998 Nov;9(11):1199-204. doi: 10.1023/a:1008478405634. Ann Oncol. 1998. PMID: 9862050 Free article. Clinical Trial.

4

[Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials].

Van Cutsem E, Peeters M. Van Cutsem E, et al. Bull Cancer. 1998 Dec;Spec No:33-7. Bull Cancer. 1998. PMID: 9932082 Review. French.

5

Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.

Van Cutsem E, Blijham GH. Van Cutsem E, et al. Semin Oncol. 1999 Feb;26(1 Suppl 5):13-20. Semin Oncol. 1999. PMID: 10213010 Clinical Trial.

6

The medical treatment of colorectal cancer: actual status and new developments.

Van Cutsem E, Peeters M, Verslype C, Filez L, Haustermans K, Janssens J. Van Cutsem E, et al. Hepatogastroenterology. 1999 Mar-Apr;46(26):709-16. Hepatogastroenterology. 1999. PMID: 10370599 Review.

7

Developments in fluoropyrimidine therapy for gastrointestinal cancer.

Van Cutsem E, Peeters M. Van Cutsem E, et al. Curr Opin Oncol. 1999 Jul;11(4):312-7. doi: 10.1097/00001622-199907000-00012. Curr Opin Oncol. 1999. PMID: 10416885 Review.

8

New directions in the treatment of colorectal cancer: a look to the future.

Sobrero A, Kerr D, Glimelius B, Van Cutsem E, Milano G, Pritchard DM, Rougier P, Aapro M. Sobrero A, et al. Among authors: van cutsem e. Eur J Cancer. 2000 Mar;36(5):559-66. doi: 10.1016/s0959-8049(99)00314-7. Eur J Cancer. 2000. PMID: 10738119 Review.

9

Oral fluoropyrimidines in colorectal cancer.

Van Cutsem E, Peeters M. Van Cutsem E, et al. Semin Oncol. 2000 Oct;27(5 Suppl 10):91-5. Semin Oncol. 2000. PMID: 11049039 Review. No abstract available.

10

The role of chemotherapy in the current treatment of gastric cancer.

Van Cutsem E, Haller D, Ohtsu A. Van Cutsem E, et al. Gastric Cancer. 2002;5 Suppl 1:17-22. doi: 10.1007/s10120-002-0219-y. Gastric Cancer. 2002. PMID: 12772882 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

719 results

Search Page